DOI: 10.1055/s-00000071

Seminars in Neurology

References

Cohen JA, Coles AJ, Arnold DL , et al; CARE-MS I investigators.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Lancet 2012;
380 (9856) 1819-1828

Download Bibliographical Data

Search in:
Access: